BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37962233)

  • 1. Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study.
    Mezőlaki NE; Baltás E; Ócsai HL; Varga A; Korom I; Varga E; Németh IB; Kis EG; Varga J; Kocsis Á; Gyulai R; Bukva M; Kemény L; Oláh J
    Melanoma Res; 2024 Feb; 34(1):54-62. PubMed ID: 37962233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
    Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
    Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
    Eggermont AM; Spatz A; Lazar V; Robert C
    Curr Opin Oncol; 2012 Mar; 24(2):137-40. PubMed ID: 22234255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
    Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
    Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of sentinel lymph node biopsy and adjuvant interferon treatment in thick (>4 mm) cutaneous melanoma: an observational study.
    Morera-Sendra N; Tejera-Vaquerizo A; Traves V; Requena C; Bolumar I; Pla A; Vázquez C; Soriano V; Nagore E
    Eur J Dermatol; 2016; 26(1):34-48. PubMed ID: 27023017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma.
    Paver EC; Ahmed T; Burke H; Saw RPM; Stretch JR; Spillane AJ; Shannon KF; Vergara IA; Elder DE; Lo SN; Thompson JF; Scolyer RA
    JAMA Dermatol; 2023 Dec; 159(12):1359-1367. PubMed ID: 37910123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis and Management of Thick and Ultrathick Melanoma.
    Blakely AM; Cohen JT; Comissiong DS; Vezeridis MP; Miner TJ
    Am J Clin Oncol; 2019 Nov; 42(11):824-829. PubMed ID: 31517636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma and IFN alpha: potential adjuvant therapy.
    Bottoni U; Clerico R; Paolino G; Corsetti P; Ambrifi M; Brachini A; Richetta A; Nisticò S; Pranteda G; Calvieri S
    J Biol Regul Homeost Agents; 2014; 28(2):271-9. PubMed ID: 25001659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
    McKenna DB; Lee RJ; Prescott RJ; Doherty VR
    Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.
    Wei X; Wu D; Chen Y; Li H; Zhang R; Yao H; Chi Z; Cui C; Bai X; Mao L; Qi Z; Li K; Lan S; Chen L; Guo R; Yao X; Lian B; Kong Y; Dai J; Tang B; Wang X; Guo J; Si L
    Br J Dermatol; 2022 Jun; 186(6):977-987. PubMed ID: 35042273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What does ulceration of a melanoma mean for prognosis?
    Callender GG; McMasters KM
    Adv Surg; 2011; 45():225-36. PubMed ID: 21954690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alpha for the adjuvant treatment of cutaneous melanoma.
    Mocellin S; Lens MB; Pasquali S; Pilati P; Chiarion Sileni V
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008955. PubMed ID: 23775773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution.
    Hinz T; Ahmadzadehfar H; Wierzbicki A; Hoeller T; Wenzel J; Biersack HJ; Bieber T; Schmid-Wendtner MH
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1316-25. PubMed ID: 22618833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of ulceration of cutaneous melanoma.
    Balch CM; Wilkerson JA; Murad TM; Soong SJ; Ingalls AL; Maddox WA
    Cancer; 1980 Jun; 45(12):3012-7. PubMed ID: 7388745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.